Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2020 and Revises Upward Full Year 2020 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. FDX
2. CBRS
3. USO
4. KBH
5. HTZ
6. SPY
7. HON
8. MRK
9. SPCX
10. TTWO

Go back to Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2020 and Revises Upward Full Year 2020 Guidance

Emergent BioSolutions (EBS) Tops Q2 EPS by $1.30, Raises Guidance

July 30, 2020 4:46 PM EDT

Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of $1.98, $1.30 better than the analyst estimate of $0.68. Revenue for the quarter came in at $394.7 million versus the consensus estimate of $294.73 million.

GUIDANCE:

Emergent BioSolutions sees Q3 2020 revenue of $420-450 million, versus the consensus of $420.2... More